FRM
DNTH icon

Fox Run Management’s Dianthus Therapeutics DNTH Stock Holding History

Fox Run Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,510
Closed -$433K – 965
2025
Q4 		$433K Buy
+10,510
New +$407K 0.07% 556

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fox Run Management's DNTH Position: Q1 2026 in Review

Fox Run Management sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 10,510 shares — an estimated $433K sold.

Fox Run Management first reported a position in DNTH in Q4 2025 and held it in 1 quarter. The position peaked at $433K in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Fox Run Management reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 10,510 Dianthus Therapeutics shares in Q1 2026, an estimated $433K.
  • Fox Run Management first reported a position in Dianthus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Fox Run Management's Dianthus Therapeutics position peaked at $433K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.